1 / 24

Organic Chemistry II 202 - DDB - 05 CAM

Organic Chemistry II 202 - DDB - 05 CAM. Aranesp By Matthew Seidler (0588687) Winter 2007 John Abbott College. Overview. Introduction What is it? History Structure/Chemistry. Benefits/Risks Competitors Personal Thoughts. Red Blood Cells.

dacian
Télécharger la présentation

Organic Chemistry II 202 - DDB - 05 CAM

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Organic Chemistry II 202 - DDB - 05 CAM Aranesp By Matthew Seidler (0588687) Winter 2007 John Abbott College

  2. Overview • Introduction • What is it? • History • Structure/Chemistry • Benefits/Risks • Competitors • Personal Thoughts

  3. Red Blood Cells • Transport oxygen to various parts of the body • Oxygen = NP, Blood = P • Need a way to transport oxygen • Divide rapidly • When your body makes fewer RBCs, anemia develops

  4. What exactly is Aranesp? • Darbepoetin alfa is a synthetic form of erythropoietin • Erythropoietin = produced by kidney, hormone that stimulates RBC production • Stimulates erythropoiesis (process by which erythrocytes (RBCs) are produced when oxygen is low (hypoxia) • Stimulates bone marrow to produce RBCs

  5. When is oxygen supply lowered? • Exercise • High altitudes, etc

  6. How EPO works • EPO binds to receptors (EpoR) in bone marrow to speed up mitosis of cells responsible for making RBCs • Oxygen in blood rises, EPO production slows down

  7. EPO

  8. Amgen, Inc. • International Biotech company in California • The largest independent biotech firm, 15K staff members • As of 09/06, Amgen had eight FDA approved drugs (one of which was Aranesp)

  9. Back to the drug… • 09/01: approved by FDA for treatment in anemia in patients with chronic renal failure • Kidneys secrete erythropoetin, which stimulates RBC production • Patients w/ renal failure commonly suffer from anemia (lower RBC count) • 06/01: approved by European Medicines Agency for the same treatments, but also for anemia patients undergoing chemotherapy • Chemotherapy affects rapidly dividing cells (I.e. RBCs) • You therefore need more erythropoetin in order to stimulate RBC production

  10. Another Use • Patients who require a blood transfusion or have surgery where blood loss is expected, EPO is given in advance • If blood is lost in surgery…

  11. How is it made? • Produced by recombinant DNA technology in modified Chinese hamster ovary cells • Differs from real erythropoietin (EPO) in that it has two more N-linked oligosaccharide chains • Why not just use real EPO?

  12. Chemistry of the drug • C815H1317N233O241S5 • Ok, let’s draw it. IHD = 1/2(2*815+2…) • Molar mass = 18396.1 g/mol

  13. Anemic Cancer Patients • 01/07, Amgen wrote a letter that highlighted the results from a recent anemia of cancer trial, and warned doctors • They informed the FDA that control over the cancer was worse in patients on Aranesp (against those who weren’t on the drug)

  14. What did the FDA say? • Released a public health advisory, in March 07, and a clinical alert for doctors about the use of erythropoeisis-stimulating agents such as epogen and darbepoeitin • Use caution when using these drugs in cancer patients • Lack of clinical evidence to support improvements in these situations

  15. Risks • Increases the risk of… • Cardiovascular problems (RBCs increases viscocity of blood) • Strokes • Hypertension • Congestive heart failure • Myocardial infarction (heart attack) • Hypertension • Seizures (why?) • Vascular thrombosis (clot inside blood vessel) • Edema (fluid collecting in cavities of body) (why?) • Side effects = fever, chest pains, nausea, etc

  16. $10 000/ yr for drug (dialysis patient)$12 000/ yr for drug (chemo patient)Sales: $10 B in 2004

  17. Abuse • Cross country skiers Larisa Lazutina & Olga Danilova of Russia and Johann Muhlegg of Spain

  18. EPO as a blood doping agent • Used by healthy athletes to give a competitive advantage • Increases oxygen carrying capacity of the blood • Therefore, increases aerobic respiratory capacity of the muscles • Helps make more ATP

  19. Continued • Useful for bicycle races (offsets decrease in RBC count that occurs over several races) • What happens if you OD? • The drug can produce so many RBCs that the blood thickens and strains the heart (I.e. during sleep when HR is low)

  20. Competitors • From Amgen: Epogen & Aranesp (Brand names) • There’s also Dynepo

  21. Dynepo • Pharmaceutical EPO under development by Shire Pharmaceuticals • Launched in Europe in 2006 • Amgen patents prevent it from launching here • Instead of being made from cultured animal cells, it’s made from cultured human cells

  22. Dynepo • Has a true form of sialic acid & oligosaccharide residues • This makes it longer lasting than Amgen’s products (this is not confirmed yet…) • Undetectible in urine tests for EPO that is used on athletes

  23. Personal Thoughts • Jehova’s Witnesses • Drug can be used for many things

  24. QUESTIONS?

More Related